Naturally occurring copper peptide that promotes wound healing, collagen and elastin synthesis, and modulates approximately 4,000 human genes involved in tissue remodeling and repair.
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide first identified in human plasma in 1973. It consists of just three amino acids — glycine, histidine, and lysine — bound to a copper(II) ion. Despite its small size, GHK-Cu has an extraordinary biological footprint: genomic studies have shown it modulates the expression of approximately 4,000 human genes, representing roughly 32% of the genome. This makes it one of the most broadly active signaling molecules known.
GHK-Cu's primary mechanisms include stimulating collagen and elastin synthesis, promoting the production of glycosaminoglycans (the structural components of connective tissue), attracting immune cells and fibroblasts to wound sites, and promoting angiogenesis. It also acts as a potent anti-inflammatory agent by suppressing pro-inflammatory cytokines including TGF-beta and TNF-alpha, while simultaneously activating tissue-remodeling pathways that reduce fibrosis and scar formation.
Beyond its wound-healing and skin-regeneration properties, GHK-Cu has demonstrated neuroprotective effects in preclinical research. It supports nerve outgrowth, reduces oxidative damage, and modulates gene expression patterns associated with cognitive decline. Its anti-fibrotic properties have implications for lung, liver, and kidney health, making GHK-Cu one of the most versatile peptides in the therapeutic arsenal — relevant across the Perform, Longevity, and Cognitive hubs.
Accelerates wound closure by attracting immune cells, stimulating fibroblast proliferation, and promoting angiogenesis at the injury site.
Stimulates collagen and elastin production, improves skin thickness and elasticity, and reduces fine lines through enhanced dermal remodeling.
Suppresses pro-inflammatory cytokines and oxidative stress markers, providing systemic anti-inflammatory support across multiple organ systems.
Supports nerve outgrowth, reduces oxidative neural damage, and modulates gene expression patterns associated with cognitive decline and neurodegeneration.
Reduces excessive scar tissue formation and fibrosis in skin, lungs, liver, and kidneys by remodeling the extracellular matrix toward healthy tissue architecture.
Looking to improve skin quality, thickness, and elasticity through collagen stimulation and enhanced dermal remodeling pathways.
Recovering from surgery, injury, or dealing with slow-healing wounds and seeking accelerated tissue repair with reduced scarring.
Interested in supporting brain health and cognitive resilience through a peptide that modulates neuroprotective gene expression.
GHK-Cu appears across multiple hubs due to its broad biological activity:
GHK-Cu was discovered by Dr. Loren Pickart in 1973 during research on human plasma proteins. Over five decades of research have established its role in wound healing, tissue remodeling, and gene modulation. Broad Connectivity Map studies have identified GHK as capable of resetting gene expression patterns of diseased cells toward healthier states. Its genomic impact — affecting approximately 4,000 genes — has been validated through multiple independent microarray analyses. GHK-Cu has an excellent safety profile and is one of the most thoroughly studied copper peptides in biomedical literature.
Cu is the chemical symbol for copper. GHK-Cu is a tripeptide (glycyl-histidyl-lysine) complexed with a copper(II) ion, which is essential for its biological activity.
GHK-Cu can be administered via subcutaneous injection or applied topically depending on the therapeutic goal. Your physician will determine the appropriate route and dosing.
Because it modulates ~4,000 genes across multiple systems, GHK-Cu has relevant applications in tissue repair (Perform), cellular longevity (Longevity), and neuroprotection (Cognitive).
The copper in GHK-Cu is bound to the peptide at physiological concentrations. However, if you have known copper sensitivity or Wilson's disease, discuss this with your physician before starting therapy.
Skin improvements typically become noticeable over 4–12 weeks as collagen synthesis and dermal remodeling progress. Wound healing benefits may be observed sooner, within 1–3 weeks.
Individual results may vary. This information is for educational purposes only. All peptide therapies require a physician evaluation and prescription.
A physician will evaluate whether GHK-Cu is right for your skin, healing, or neuroprotection goals.
Check Your Eligibility →